| 1 | The external validity of machine learning-based prediction scores from hematological |
|----|--|
| 2 | parameters of COVID-19: A study using hospital records from Brazil, Italy, and Western |
| 3 | Europe |
| 4 | |
| 5 | Ali Akbar Safdari ^{1#} , Chanda Sai Keshav ^{1#} , Deepanshu Mody ^{1#} , Kshitij Verma ^{1#} , Utsav |
| 6 | Kaushal ^{1#} , Vaadeendra Kumar Burra ^{1#} , Sibnath Ray ² , Debashree Bandyopadhyay ^{1*} |
| 7 | 1. Department of Biological Sciences, Birla Institute of Technology and Science, Pilani, |
| 8 | Hyderabad Campus, Hyderabad, Telangana, 500078 |
| 9 | 2. Gencrest Private Limited, 301-302, B-Wing, Corporate Center, Marol Pipeline Road, Andheri |
| 10 | Kurla Road, Mumbai, 400059 |
| 11 | *corresponding author |
| 12 | # equal contribution (names are arranged alphabetically) |
| 13 | |
| | |

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice 1

14

15 Abstract:

16 Background

The COVID-19 pandemic is the deadliest threat to humankind caused by the SARS-COV-2 17 18 virus in recent times. The gold standard for its detection, quantitative Real-Time Polymerase Chain Reaction (gRT-PCR), has several limitations regarding experimental handling, 19 expense, and time. While the hematochemical values of routine blood tests have been 20 21 reported as a faster and cheaper alternative, the external validity of the model on a diverse 22 population has yet to be thoroughly investigated. Here we studied the external validity of machine learning-based prediction scores from hematological parameters recorded in Brazil, 23 24 Italy, and Western Europe.

25 Methods and Findings

26 The publicly available hematological records (raw sample size (n) = 195554) from hospitals of 27 three different territories, Brazil, Italy, and Western Europe, were preprocessed to develop the 28 training, testing, and prediction cohorts for ML models. A total of eight (sub)datasets were trained on seven different ML classifiers. The XGBoost classifier performed consistently better 29 30 on all the datasets producing eight different models. The working models include a set of either four or fourteen hematological parameters. The internal performances of the XGBoost models 31 (AUC scores range from 84% to 97%) were superior to the ML models reported in the literature 32 for a few datasets (AUC scores range from 84% to 87%). The external performance (AUC 33 score) was 86% when the model was trained and tested on fourteen hematological parameters 34 obtained from the same country (Brazil) but on independent datasets. However, the external 35 performances were reduced when tested across the populations; 69% when trained on 36 37 datasets from Italy (n=1736) and tested on datasets from Brazil (n=602)) and 65%, when trained on datasets from Italy and tested on datasets from Western Europe (n=1587)) 38 respectively. 39

40 Conclusion

For the first time, this report showed that the models trained and tested on the same population but on separate records produced reasonably accurate results. The study promises the confidence of these models trained and tested within the same populations and has the potential application to extend those to other demographic locations. Both four- and fourteenparameter models are publicly available; <u>https://covipred.bits-hyderabad.ac.in/home</u>

46 Author Summary:

COVID-19 has posed the deadliest threat to the human population in the 21st century. Timely 47 detection of the disease could save more lives. The RT-PCR test is considered the gold 48 standard for COVID-19 detection. However, there are several limitations of the technique that 49 suggests developing an alternate detection protocol that would be efficient, fast, and cheap. 50 Among several other alternate detection techniques, hematology based Machine-Learning 51 (ML) prediction is one. All the hematology-based predictions reported so far in the literature 52 were only internally validated. Considering the need to develop an alternate protocol for rapid, 53 54 near-accurate, and cheaper COVID-19 detection techniques, we aim to externally validate the hematology-based ML prediction. Here external validation indicates use of two independent 55 datasets for model training and testing, in contrast to internal validation where the same 56 dataset splits into train and test sets. We have integrated published clinical records from Brazil, 57 58 Italy, and West Europe hospitals. Internal ML model performances are superior compared to 59 those reported in literature. The external model performances were equivalent to the internal 60 performances when trained and tested on the same population. However, the external 61 performances were inferior when train and test sets were from different populations. The 62 results promise the utility of these models on the same populations. However, it also warns to 63 train the model on one population and test it on another. The outcome of this work has the potential for an initial screen of COVID-19 based on hematological parameters before gRT-64 PCR tests. 65

66

67

68 Introduction:

The COVID-19 infection has posed the deadliest threat to the health of the human population in the 21st century. Likely, the danger is far from over concerning the emerging variants of COVID-19, such as alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2), lambda

(C.37), and omicron (B.1.1.529)¹, along with other frequently mutating respiratory diseases, 72 like, influenza virus A (H1N1)². Due to the nature of the disease, timely detection of COVID-73 19 is of utmost importance. Hence, detection techniques play a pivotal role in its diagnosis. 74 The gold standard of COVID-19 detection is quantitative Real-Time Polymerase-Chain-75 76 Reaction (qRT-PCR). This method has several limitations, like manual errors during sample (nasal and oral swab) collection, operational errors, etc.³. Moreover, the time required for the 77 experiment and availability of the detection kits at a mass level becomes difficult in a vast 78 79 population with a large number of infections. The test is also costly for low-income groups. An 80 accurate, rapid, and low-cost prediction strategy would supplement the initial screening, particularly in a country like India, with the second-largest population in the world. 81

82 The most common clinical feature of severe COVID-19 is pneumonia with fever, cough, 83 fatique, headache, diarrhea, hypoxia, and dyspnoea. The latest variant, omicron, has some 84 common symptoms with the earlier SARS-COV-2 strains, although with lesser severity due to 85 mild infection in the lower respiratory tract and reduced probability of hospitalization¹. In the 86 case of mild COVID-19 infection, either no (asymptotic) or only mild pneumonia is observed. In moderate infection, dyspnoea, hypoxia, and lung injury may occur. In severe infection, 87 88 respiratory failure to multi-organ failure occurs. In brief, severe cases of COVID-19 can lead to a systemic infection affecting almost all of the major organ systems. As a result, patients of 89 90 COVID-19 exhibit a wide range of hematologic abnormalities that changes with disease progression, severity, and mortality ⁴. For example, the white blood cells sense and respond 91 to the microbial threats ⁵; blood platelet expression and platelet counts are altered ⁶⁷ - platelet 92 hyperactivity was demonstrated as one of the unique features of COVID-19 infection⁸. Hence, 93 a complete blood count (CBC) could serve as a biomarker for COVID-19. Screening the 94 COVID-19 infection in terms of CBC has been attempted by various research groups 95 worldwide, ^{9 10 11 12 13 14}. 96

Some of these research groups used machine learning (ML) approaches to exploit the CBC
parameters from a specific population for disease prediction; the Area Under Curve (AUC)

99 performance ranges from 84% to 87% in those models. So far, no report is available to test the applicability of the hematology-based ML models across different ethnicity and 100 populations. The combination of CBC parameters varies with ethnicity. However, some blood 101 parameters alteration, such as lymphocytopenia¹⁵¹⁶ leucopenia, and thrombocytopenia¹⁷¹⁸ 102 103 ¹⁹, are common due to COVID-19. In this work, we combined different hematological parameters from various populations to develop the optimal ML models and tested them on 104 independent datasets obtained from other populations. Standardization across different ML 105 106 algorithms yields eXtreme Gradient Boost (XGBoost) as the best-performing model across the 107 datasets compared to published literature. For the first time, we report the external validity of the prediction scores trained, tested, and predicted across the populations. The models 108 performed the best when trained and tested on the same population but on different records 109 110 (datasets).

111

112 Method:

Description of clinical datasets for training, validation, and prediction:

114 Dataset 1:

Dataset-1 was generated based on anonymized patient data publicly available from Hospital Israelita Albert Einstein, in São Paulo, Brazil <u>https://www.kaggle.com/einsteindata4u/covid19</u>. The data were recorded from February 26th, 2020, to March 23rd, 2020. The cases and controls for this dataset include the patients whose samples were collected to perform the SARS-CoV-2 qRT-PCR and additional laboratory tests during a visit to the hospital.

The initial data set consisted of 558 positive and 5086 negative cases of COVID-19. This dataset was processed to minimize the null-value columns and eliminate the negative instances with many null values. The value (x_i) in each cell was pre-normalized (at the source) to a mean value (μ) of zero and a unit standard deviation (σ); this was termed as 'normalized count'; $x_i' = (x_i - \mu)/\sigma$. The same normalization scheme has been used throughout the

subsequent datasets. The columns with null values appearing more than 90% were dropped. 125 126 The records (rows) showing positive results were retained by default, and the negative records were maintained only with more than 10% non-null entries. This processed dataset, termed 127 dataset 1, contains thirty-seven features and 2004 records, 558 positives and 1446 negatives 128 129 (Table 1). The negative to positive sample size ratio, 2.59, is four times less than that in the published model (11.51)⁹. Here 'features' refer to x-parameters used to train the model; the 130 definition excludes the y-parameter, SARS-COV2 results (positive or negative). This definition 131 132 is consistently used in the subsequent datasets. These thirty-seven features were categorized into four classes, namely, i) age, ii) severity of the infection, iii) hematological features, and iv) 133 co-morbidities (Table S1). 134

- 135
- 136 Table 1: Statistics of the datasets

| Dataset | No. of | No. | No. of | Default | No. of |
|---|---------|-----------|-----------|--------------|----------|
| | entries | positive | negative | scale_poswei | features |
| | (P+N) | cases (P) | cases (N) | ght (=N/P) | used |
| 1 (i) | 2004 | 558 | 1446 | 2.59 | 37 |
| 1a | 602 | 83 | 519 | 6.25 | 18 |
| 1b | 602 | 83 | 519 | 6.25 | 14 |
| 1c | 602 | 83 | 519 | 6.25 | 4 |
| 2a (ii) | 1388 | 765 | 623 | 0.81 | 31 |
| 2b | 1736 | 816 | 920 | 1.13 | 4 |
| 3a (iii) | 5872 | 1772 | 4100 | 2.31 | 21 |
| 3b | 12105 | 8926 | 3176 | 0.356 | 14 |
| https://www.kaggle.com/einsteindata4u/covid19 | | | | | |

137

https://www.kaggle.com/einsteindata4u/covid19





II. https://zenodo.org/record/4081318#.X4RWqdD7TIU

III. https://repositoriodatasharingfapesp.uspdigital.usp.br/

Dataset 1a: A subset of dataset 1 was curated with eighteen features – patient age quantile,
three hospitalization conditions, namely, patients admitted to regular ward, semi-ICU, and
ICU, and fourteen hematological parameters. Co-morbidities were excluded from dataset 1a.
The total number of records was 602, with 83 positives and 519 negatives.

Dataset 1b: A subset of dataset 1 was curated based on hematological features only. Other parameters, namely, co-morbidities, patient age quantile and patient admission status, were dropped in this dataset. All features with fewer than 90% of non-null values were dropped. All the records that have 100% null values were dropped. The preprocessing resulted in a dataset of fourteen hematological features and 602 records, 83 positives, and 519 negatives. Thus, the negative-to-positive sample size ratio was 6.25.

Dataset 1c: A third subset of dataset 1 (dataset 1c) was curated from dataset 1b based on four blood count features (Figure 1) that have shown a higher correlation with the qRT-PCR results. The number of records, positives, and negatives are identical to dataset 1b. These four blood count features were also reported as significant for SARS-COV-2 infection in published literature⁹.

156

157 *Dataset 2:*

This dataset was obtained from San Raphael Hospital (OSR), Italy¹¹. In the original OSR dataset, there were 1736 entries with a total of 72 features, and those included 36 hematological features. The samples were collected from patients admitted to OSR from February to May 2020. Fifty-two percent of the patients were COVID-19 positive.

162

Dataset 2a: These 1736 entries were processed such that all rows (records) with more than 66% null values were dropped. The processed dataset contained 1388 records, 765 positives, and 623 negatives. This dataset includes 31 features: age, sex, a feature for suspicion (representing subjective analysis of the patient by a physician), and 28 hematological parameters (Figure 1). The ratio of negative to positive records was 0.81.

168 **Dataset 2b:** A subset of dataset 2 was curated with only four blood count parameters (similar

to dataset 1c). No columns or rows were dropped here, as there were no rows with less than

170 66% null values. Dataset 2b has 1736 records, 816 positives, and 920 negatives.

171

172 Dataset 3:

173 Dataset 3 was obtained from the Covid Data Sharing initiative created by a consortium led by

174 FAPESP (Sao Paulo Research Foundation) and USP (University

of Sao Paulo, Brazil). The data originated from three prominent private hospitals in Sao Paulo,

176 Brazil - Fleury Institute, Sírio-Libanês Hospital, and Albert Einstein Hospital, from November 1st,

177 2019, to July 1st, 2020 (https://repositoriodatasharingfapesp.uspdigital.usp.br/). The data was

anonymized from patients tested for COVID-19 (serology or RT-PCR).

The raw data obtained from the data sharing initiative had multiple rows (records) corresponding to individual patients containing different clinical features ("long-form" of the dataset). The "long form" of the dataset was converted, using an in-house python code, to the "wide form," where one row corresponds to all the clinical features of a patient. The "wide form" of the dataset has 189227 records and 454 features. These 454 features were common, as there were duplicates in the column headers (due to different reference ranges) for some features. After deduplication, the feature number was reduced to 104.

Dataset 3a: The non-duplicated features were further filtered by excluding the following conditions, i) no qRT-PCR results available, ii) all the rows with more than 66% null values, and iii) the Pearson correlation of that particular feature (for the SARS-COV-2 results) less than 0.05. A total of twenty-one hematological indices (features) were identified based on the above cutoff (Figure 1). The final dataset contains 5872 records, 1772 positives, and 4100 negatives.

Dataset 3b: The deduplicated 'wide form' of the data (189227 records and 104 features) were
filtered with the following conditions – a) qRT-PCR results present, b) records with null values

- less than 66%, and c) fourteen hematological parameters present, as in dataset 1b. The total
- number of records present in the dataset was 12105 records.
- All the processed datasets have a 90:10 split between the training and the test data.
- 197

Description of the clinical dataset for blind prediction:

199 Western European dataset:

This dataset was obtained from several hospitals in Western Europe (Table S2). The dataset includes the patients from the first day of hospitalization to nearly five weeks¹³. This published data was in the form of twenty separate tables that we merged into a single file comprising 2587 entries and thirty-seven features. According to the source authors13, there are two stages of the disease, a) early stage, from day zero through three (total of four days), and b) advanced stage, comprising all the subsequent days. This blind prediction dataset includes only four hematological parameters consistent with dataset-2b.

207

208 Machine Learning (ML) approaches:

The machine learning (ML) algorithms were implemented in Python (3.7.13) using the following libraries, Numpy (1.21.6), Pandas (1.3.5), XGBoost (0.90), Scikit-learn (1.0.2), Seaborn (0.11.2), Matplotlib (3.2.2) and Pickle 4.0 libraries.

212 Different algorithms:

The algorithm primarily employed was the Extreme Gradient Boost (XGBoost) classifier that 213 implements gradient-boosted decision trees (with enhanced speed and performance) and 214 trains a class-weighted (or cost-sensitive) version of imbalanced classification²⁰. XGBoost, a 215 ternary classifier, considers null entries one of the classes that handle the null-entry values. 216 Other classifiers tested on these datasets were logistic regression, Fischer linear discriminant 217 Naïve Bayes, SVM, random forest, and K-Nearest Neighbor (KNN). Logistic regression 218 predicts the output of a categorical dependent variable by fitting an "S" shaped logistic function 219 that indicates two maximum values, 0 or 1. Fischer linear discriminant classifier maximizes 220

221 the separation between the projected class means and minimizes the class overlap leading to well-separated classes. Naive Bayes is a classification technique based on the Bayes theorem 222 223 with an assumption of independent predictors; a particular feature is independent of another 224 feature in a class. The SVM algorithm aims to create the best line or decision boundary to 225 segregate n-dimensional space into classes to accommodate a new data point. The best 226 decision boundary, a hyperplane, is made based on the extreme points (vectors). Random 227 forest is a concept of ensemble learning – a combination of multiple classifiers to solve a 228 complex problem and improve the model performance. As the name suggests, Random Forest 229 contains several decision trees on various subsets of the given dataset and takes the average to improve the predictive accuracy of that dataset. KNN algorithm stores all the available data 230 and classifies a new data point based on the similarity by placing a new data point in the 231 232 nearest category. Thus, new data belongs to an appropriate class.

233 Hyper-parameter used in XGBoost classifier:

To normalize the imbalance in the number of negative and positive data points in the XGBoost 234 classifier, hyper-parameter "scale pos weight" 235 https://xgboost.readthedocs.io/en/stable/parameter.html#parameters-for-tree-booster, 236 was 237 introduced. The scale_pos_weight value was used to scale the gradient for the positive class. For example, the "scale_pos_weight" = 2 indicates twice the weight of the positive class 238 compared to the negative class. It also overcorrects the misclassification of the positive class. 239 The loss curve (optimized to get a better model) will be affected differently in case of positive 240 and negative entry misclassification. However, large scale_pos_weight can help the model 241 achieve better performance for the positive class prediction (overfitting the positive class) at 242 the cost of worse performance on the negative or both classes. Hence we have consistently 243 244 considered the default scale-pos-weight (the ratio of numbers of negative to positive entries) 245 throughout this report.

246 Imputation for other ML models:

247 Unlike XGBoost, most ML algorithms cannot handle null values, thus requiring data imputation. We imputed missing values through the IterativeImputer module in the ScKit-learn 248 package (https://scikit-learn.org/stable/modules/impute.html#multivariate-feature-imputation), 249 which imputes values for null data points for each feature iteratively. It does so by fitting a 250 251 regressor to the other feature columns (X-parameter) for records with known values of the target feature (y-parameter) and then predicts missing values of the target feature. 252 253 Performance metrics: 254 The performance metrics used were accuracy, specificity, and sensitivity, defined by true

positives (TP), true negatives (TN), false positives (FP), and false negatives (FN) (eq 1-3).

256 Accuracy = (TP+TN)/(TP+TN+FP+FN).....Eq.1

257 Specificity = (TN/TN+FP).....Eq.2

258 Sensitivity = (TP/TP+FN).....Eq.3

The fourth metric was the Area Under the ROC Curve (AUC). The AUC was computed from 259 roc_auc_score 260 prediction using the (https://scikitscores 261 learn.org/stable/modules/generated/sklearn.metrics.roc auc score.html) module of the sklearn-metrics library. A ROC curve (Receiver Operating Characteristic curve) plots the 262 263 performance (True Positive Rate (TPR) versus False Positive Rate (FPR)) of a classification model at all classification thresholds. TPR is synonymous with sensitivity, also known as recall. 264 FPR is FP/(FP + TN). AUC measures the Area under ROC (as defined by TPR versus FPR) 265 curve from (0,0) to (1,1) along the x-axis (FPR axis). AUC ranges from 0 to 1; 0 implies a 266 100% wrong model, and 1 indicates a 100% correct model. 267

268

269 Design of the web server:

The web server hosted two different models, a four-hematological parameter model and a fourteen-hematological parameter model. The web server was developed on an HTML framework, with five working HTML files: a landing page and two pages each for each method, one for data input and the other for prediction display. The basic skeleton of the HTML files

was formatted with CSS code, and these files were deployed via the python module, Flask.

275 Python libraries, like numpy and pandas, were used to collect and process the input, with the

- 276 responses generated by the XGBoost models.
- 277
- 278

279 Results and Discussion:

280 Clinical datasets exploited for feature selection:

Three independent clinical datasets (dataset 1, dataset 2, and dataset 3) were curated and processed from hospitals in Brazil and Italy (Figure 2). Hematological features were selected from these datasets based on the Pearson correlation coefficients computed between the features and the SARS-COV-2 results (positive or negative) (Figure 3).

285 For dataset-1, four features (out of thirty-seven) showed higher correlation values (cutoff value 286 $\sim \pm 0.2$) with SARS-COV-2 results. These four features were platelet counts, monocytes, 287 eosinophils, and leukocytes (all reported in 10^9/L). Only monocytes have shown a significant increase in their values in SARS-COV-2 patients (positive correlation). The remaining 288 parameters decreased during infection (negative correlation). Careful observation revealed 289 290 that in the case of non-admitted patients, monocyte increase is maximum, suggesting that innate immunity is handling the infection. On the other hand, platelet volume (MPV) increased, 291 and platelet counts decreased in the case of regular ward patients, clearly indicating the 292 increase in platelet size. Thus the immune system will be affected, and the number of immune 293 cells will decrease, justifying the negative correlation of eosinophil, leukocytes, and platelet 294 count with SARS-COV-2 disease. The low platelet counts accounted for severe COVID-19 295 patients, even down in non-survivors compared to the survivors ²¹. The correlation coefficient 296 297 values between SARS-COV-2 results and different features reported elsewhere were similar 298 to this observations¹¹. Hence, dataset-1c was developed on these four features.

For dataset 2a, eight features (out of twenty-eight) have shown correlation values outside the cutoff. Those features were i) aspartate aminotransferase, ii) lactate dehydrogenase, iii) leukocyte (10^9/L), iv) eosinophil (%), v) basophil (%), vi) eosinophil count, vii) lymphocyte count and viii) basophil count (all the counts in 10^9/L). Two features: Aspartate aminotransferase and lactate dehydrogenase have increased in COVID-19 patients. The remaining other hematological features decreased. In datasets 1c and 2a, there are two features, leukocyte count and eosinophil count, commonly drop with SARS-COV-2 results that presumably indicate that despite variable immune response in different populations, some hematological features are common in SARS-COV-2 disease across the populations.

For dataset 3a, four parameters, lactate dehydrogenase, partial oxygen pressure in the artery, serum ferritin, and serum magnesium, have a higher positive correlation (>0.1) with SARS-COV-2 results. Whereas basophil, eosinophil, leukocyte, and lymphocyte counts have a higher negative correlation (<-0.1) with SARS-COV-2 results. In datasets 1c, 2a, and 3a, two clinical features, leukocyte count and eosinophil count, were common.

313 Comparative performances of seven different ML models on current datasets:

Eight datasets (Figure 2) from three primary datasets, 1, 2, and 3, were derived based on 314 either higher correlation with SARS-COV-2 results or to make parity (in terms of the number 315 of features) with other datasets. The overall statistics of these eight datasets are shown (Table 316 317 1). Different ML models were trained on these datasets. The performances were measured using the receiver operating characteristic (ROC) curves (Figure 4). XGBoost outperformed 318 other methods for all datasets except dataset 1a. The internal evaluation showed that the 319 XGBoost model outperformed all the datasets when all four performance metrics, namely, 320 accuracy, sensitivity, specificity, and AUC scores, were considered together (Table S3). 321

Datasets-1 and 1c have shown optimal performances (AUC scores 0.94 and 0.97, respectively) in all four metrics. For dataset 1c, sensitivity was observed as 1.0, indicating 100% correct prediction of True Positive (TP) values, presumably, due to overcorrection of the TP values in a small dataset (n=602) with a low population of positives (n=83), leading to large *scale-pos-weight* of 6.25. As mentioned in the method section, large *scale-pos-weight* improves the performance of the positive class prediction at the cost of the negative class 328 prediction. The XGBoost models, when compared with the other models, in terms of all the metrics, the notable observation was low sensitivity values for dataset 1 (small sample size, 329 n=602) and allied subsets (datasets, 1a to 1c) for almost all the models except Naïve Bayes 330 331 classifier. The low sensitivity values for datasets 1b and 1c are presumably attributed to the 332 smaller size and shallow positive populations in those datasets. Most likely, the XGBoost, 333 being a ternary classifier, can more effectively handle the class imbalance than the imputations 334 performed in other ML methods. However, the low sensitivity problem was absent in datasets 335 2a and 2b, as the number of positives and negatives were equivalent (Table 1).

336

337 Comparison of internal performances of the XGBoost model with published reports:

The internal performances of the XGBoost model were compared with reported methods from the published literature^{9 11}. The results from the XGBoost model outperformed the published reports (Table 2 and Figure 5).

341

Table 2: Internal evaluation of the XGBoost model on different datasets and comparison with

| Dataset | Sensitivity | Specificity | Accuracy | AUC score | Published |
|---------|-------------|-------------|----------|-----------|---------------|
| | | | | | AUC score |
| 1 | 0.826 | 0.974 | 0.940 | 0.941 | |
| 1a | 0.875 | 0.925 | 0.918 | 0.967 | |
| 1b | 0.750 | 0.887 | 0.869 | 0.922 | 0.87 (ref 8) |
| 1c | 1.000 | 0.906 | 0.918 | 0.939 | 0.87 (ref 8) |
| 2a | 0.830 | 0.843 | 0.835 | 0.906 | 0.84 (ref 10) |
| 2b | 0.845 | 0.733 | 0.787 | 0.842 | |
| 3а | 0.719 | 0.799 | 0.776 | 0.835 | |
| 3b | 0.784 | 0.733 | 0.746 | 0.842 | |

343 published datasets

345 Selection of working XGBoost models for external evaluation across the populations:

As per the results, the XGBoost model performed the best on dataset 1c, having four 346 hematological parameters. However, the performance of the XGBoost model on dataset 1b, 347 348 having fourteen hematological parameters, was comparable to that of dataset 1c, with a 349 slightly lower AUC Score (0.94 versus 0.92). Based on these observations, we hypothesize 350 both four-parameter and fourteen-parameter models as the working ML models for COVID-19 351 testing and blind predictions across different populations. Although the internal performances 352 were the best with datasets 1a and 1c, the overfitting of the data due to small sample sizes 353 was an issue, as discussed above. Hence, we selected two other XGBoost models with four and fourteen parameters obtained from datasets 2b (Italy) and 3b (Brazil), albeit with a slightly 354 lowered AUC score of 0.842 in both cases. These two were the final working models (training 355 356 dataset) for external evaluation.

357

358 External evaluation of XGBoost models with four hematological parameters across Italian and 359 Brazilian populations:

External evaluation for the four-parameter model was performed on the test dataset 1c from Brazil. Note that the training dataset 2b was from Italy. The sensitivity was 0.81 with a lower specificity value; the AUC score was 0.69 (Table 3a). For the first time, an ML model was trained on one ethnic group and tested on another ethnic group with reasonably good performance.

365

Table 3: External evaluation of XGBoost algorithm based on a) 4- hematological features andb) 14-hematological features trained and tested across different datasets.

368 a)

| Training set/test | Sensitivity | Specificity | Accuracy | AUC Score |
|-------------------|-------------|-------------|----------|-----------|
| set | | | | |

| Dataset 2b | 0.81 | 0.45 | 0.50 | 0.69 |
|-------------|------|------|------|------|
| (Italian) / | | | | |
| dataset 1c | | | | |
| (Brazilian) | | | | |
| | | | | |

369

370 b)

| Training | Sensitivity | Specificity | Accuracy | AUC Score |
|---------------|-------------|-------------|----------|-----------|
| set/test set | | | | |
| Dataset 3b | 0.55 | 0.90 | 0.85 | 0.86 |
| (Brazilian) / | | | | |
| dataset 1b | | | | |
| (Brazilian) | | | | |
| | | | | |

371

372 External evaluation of XGBoost models with fourteen hematological parameters within the

373 Brazilian populations:

The fourteen-parameter XGBoost model was trained on dataset 3b (n=12105) and tested on 374 375 dataset 1b (n=602), both from Brazilian populations. However, the samples in these two 376 datasets were from different time points; hence those can be considered independent data sources. The AUC score for this prediction was 0.86 (Table 3b). These results were better 377 378 than the performance for the four-feature XGBoost model across the populations. There could 379 be multiple reasons for the better performance of the fourteen-feature model over the four-380 feature model, a) the larger size of the training dataset, b) training and prediction data obtained from the same demographic location, that is, Brazil, and c) combination of more number of 381 features with a larger dataset, presumably, yields to a better result. 382

Blind prediction of XGBoost models with four hematological parameters on West European
 populations:

To further validate the efficacy of the working models, we have considered one more dataset 386 from published literature with thirty-seven features, including the data points along different 387 stages (time points) of COVID-19¹³. The dataset was from the literature without preprocessing 388 (no feature, records, or data points removed). According to the source authors, two distinct 389 stages of COVID-19 patients, W.E.-early and W.E.-advanced. 390 Distributions of four hematological parameters across the datasets, 1c, 2b, W.E.-early, and W.E.-advanced, were 391 compared (Figure 6). The distributions were almost the same across all the datasets for 392 393 Leukocytes and platelets. For eosinophils and monocytes, the distributions for datasets 2b and W.E.-early are very similar. Moreover, distributions across datasets 1c and W.E.-394 395 advanced were similar for the same features. The external performance of the model on W.E.early dataset (0.65) was high compared to that on W.E.-advanced dataset (0.52) (Table 4). 396 397 To note, W.E.-early and W.E.-advanced datasets contain information only from COVID-19 398 patients and no negative controls. Hence, only the sensitivity metric was reported (Table 4).

399

Table 4: Blind prediction of XGBoost model trained on dataset 2b and tested on W.E.-*early*and W.E.-*advanced* datasets. The *early* and *advanced* datasets contain only COVID-19positive patient results; no negatives were available. Hence, only sensitivity values reported

| Training set/test set | Sensitivity |
|------------------------|-------------|
| Dataset 2b/ W.Eearly | 0.65 |
| Dataset 2b/W.Eadvanced | 0.52 |

403

404 Deployment of Prediction server:

We deployed a web server where two sets of inputs are acceptable for binary COVID-19 prediction, i) four hematological parameters (leukocyte, monocyte, eosinophil, and platelet count) and ii) fourteen-parameter models in the following URL link, https://covipred.bits-

hyderabad.ac.in/home. Different pages on the webserver are shown (Figure 7). The server
outputs the COVID-9 results, either positive or negative, with the COVID-19 probability
reported in percentage.

411 Conclusion:

412 Considering the need to develop an alternate protocol for rapid, near-accurate, and cheaper COVID-19 detection techniques, we aimed to externally validate the hematology-based ML 413 prediction reported in the literature with internal evaluation only. We have integrated published 414 clinical records from Brazil, Italy, and West Europe hospitals. The data from Brazil and Italy 415 were classified into eight datasets and trained on seven different ML methods; the XGBoost 416 417 algorithm was the best. The internal performances of the XGBoost models were better than the published reports on the same datasets. Four and fourteen-parameter XGBoost models 418 were selected for external evaluations. The external performance of the fourteen-parameter 419 420 XGBoost model trained and tested on the Brazilian dataset was similar to that of the internal 421 performance. However, the external performances of the four-parameter XGBoost model trained on the Italian dataset and tested on a) Brazilian and b) West European datasets were 422 poorer than the previous one. The results promise the utility of these models when trained and 423 424 tested on the same populations. However, it also warns to use the model, with caution, trained 425 on one population and test on another. The outcome of this work has the potential for an initial 426 screen of COVID-19 based on hematological parameters before qRT-PCR tests. In future 427 work, we aim to train and test those on the Indian population to use at the healthcare centers of India. 428

429

430

431 Funding Information: DB gratefully acknowledges DST-MATRICS (COVID-19 special 432 call) Govt. of India, Grant/Award number: MSC/2020/000498, for funding this project.

AAS acknowledges CSIR, India, for Junior and Senior Research Fellowships, Award Number: 09/1026(0033)/2020-EMR-I

- 435
- 436 References:
- 437 (1) Menni, C.; Valdes, A. M.; Polidori, L.; Antonelli, M.; Penamakuri, S.; Nogal, A.; Louca,
- 438 P.; May, A.; Figueiredo, J. C.; Hu, C.; Molteni, E.; Canas, L.; Österdahl, M. F.; Modat,
- 439 M.; Sudre, C. H.; Fox, B.; Hammers, A.; Wolf, J.; Capdevila, J.; Chan, A. T.; David, S.
- 440 P.; Steves, C. J.; Ourselin, S.; Spector, T. D. Symptom Prevalence, Duration, and
- 441 Risk of Hospital Admission in Individuals Infected with SARS-CoV-2 during Periods of
- 442 Omicron and Delta Variant Dominance: A Prospective Observational Study from the
- 443 ZOE COVID Study. *www.thelancet.com* **2022**, *399* (10335), 1618–1624.
- 444 https://doi.org/10.1016/S0140-6736(22)00327-0.
- 445 (2) Lubna, S.; Chinta, S.; Burra, P.; Vedantham, K.; Ray, S.; Bandyopadhyay, D. New
- 446 Substitutions on NS1 Protein from Influenza A (H1N1) Virus: Bioinformatics Analyses
- 447 of Indian Strains Isolated from 2009 to 2020. *Heal. Sci. Reports* **2022**, 5 (3), e626.
- 448 https://doi.org/10.1002/hsr2.626.
- (3) Syal, K. Guidelines on Newly Identified Limitations of Diagnostic Tools for COVID-19
- 450 and Consequences. J. Med. Virol. 2021, 93 (4), 1837–1842.
- 451 https://doi.org/10.1002/JMV.26673.
- 452 (4) Taj, S.; Kashif, A.; Arzinda Fatima, S.; Imran, S.; Lone, A.; Ahmed, Q. Role of
- 453 Hematological Parameters in the Stratification of COVID-19 Disease Severity. *Ann.*
- 454 *Med. Surg.* **2021**, *6*2, *6*8–72. https://doi.org/10.1016/J.AMSU.2020.12.035.
- 455 (5) Beadling, C.; Silfka, M. M. No TQuantifying Viable Virus-Specific T Cells without a
- 456 Priori Knowledge of Fine Epitope Specificityitle. *Nat. Med.* **2006**, *12*, 1208–1212.
- 457 https://doi.org/https://doi.org/10.1038/nm1413.
- 458 (6) Kanth Manne, B.; Denorme, F.; Middleton, E. A.; Portier, I.; Rowley, J. W.; Stubben,
- 459 C.; Petrey, A. C.; Tolley, N. D.; Guo, L.; Cody, M.; Weyrich, A. S.; Yost, C. C.;

- 460 Rondina, M. T.; Campbell, R. A. Platelet Gene Expression and Function in Patients
- 461 with COVID-19. *Blood* **2020**, *136* (11), 1317–1329.
- 462 https://doi.org/10.1182/blood.2020007214.
- 463 (7) Güçlü, E.; Kocayiğit, H.; Okan, H. D.; Erkorkmaz, U.; Yürümez, Y.; Yaylacı, S.;
- 464 Koroglu, M.; Uzun, C.; Karabay, O. Effect of COVID-19 on Platelet Count and Its
- 465 Indices. *Rev. Assoc. Med. Bras.* **2020**, 66 (8), 1122–1127.
- 466 https://doi.org/10.1590/1806-9282.66.8.1122.
- 467 (8) Comar, S. P. et. al. COVID-19 Induces A Hyperactive Phenotype in Circulating
- 468 *Platelets*; 2020. https://doi.org/doi: https://doi.org/10.1101/2020.07.24.20156240.
- 469 (9) Banerjee, A.; Ray, S.; Vorselaars, B.; Kitson, J.; Mamalakis, M.; Weeks, S.; Baker, M.;
- 470 Mackenzie, L. S. Use of Machine Learning and Artificial Intelligence to Predict SARS-
- 471 CoV-2 Infection from Full Blood Counts in a Population. Int. Immunopharmacol. 2020,
- 472 86 (May), 106705. https://doi.org/10.1016/j.intimp.2020.106705.
- 473 (10) Djakpo, D. K.; Wang, Z.; Zhang, R.; Chen, X.; Chen, P.; Ketisha Antoine, M. M. L.
- 474 Blood Routine Test in Mild and Common 2019 Coronavirus (COVID-19) Patients.

475 *Biosci. Rep.* **2020**, *40* (8), 1–5. https://doi.org/10.1042/BSR20200817.

- 476 (11) Federico, C.; Andrea, C.; Davide, F.; Chiara, D. R.; Daniele, C.; Eleonora, S.;
- 477 Alessandra, C.; Elena, D. V.; Giuseppe, B.; Massimo, L.; Anna, C. Development,
- 478 Evaluation, and Validation of Machine Learning Models for COVID-19 Detection
- 479 Based on Routine Blood Tests. *Clin. Chem. Lab. Med.* **2020**, *59* (2), 421–431.
- 480 https://doi.org/10.1101/2020.10.02.20205070.
- 481 (12) Brinati, D.; Campagner, A.; Ferrari, D.; Locatelli, M.; Banfi, G.; Cabitza, F. Detection of
- 482 COVID-19 Infection from Routine Blood Exams with Machine Learning: A Feasibility
- 483 Study. J. Med. Syst. **2020**, 44, 135. https://doi.org/10.1101/2020.04.22.20075143.
- 484 (13) Linssen, J.; Ermens, A.; Berrevoets, M.; Seghezzi, M.; Previtali, G.; van der Sar-Van
- der Brugge, S.; Russcher, H.; Verbon, A.; Gillis, J.; Riedl, J.; de Jongh, E.; Saker, J.;
- 486 Münster, M.; Munnix, I. C. A.; Dofferhoff, A.; Scharnhorst, V.; Ammerlaan, H.;

- 487 Deiteren, K.; Bakker, S. J. L.; van Pelt, L. J.; de Hingh, Y. K.; Leers, M. P. G.; van der
- 488 Ven, A. A Novel Haemocytometric COVID-19 Prognostic Score Developed and
- 489 Validated in an Observational Multicentre European Hospital-Based Study. *Elife* **2020**,
- 490 9 (e63195), 1–28. https://doi.org/10.1101/2020.09.27.20202168.
- 491 (14) Abdullah, I.; Cornelissen, H. M.; Musekwa, E.; Zemlin, A.; Jalavu, T.; Mashigo, N.;
- 492 Chetty, C.; Nkosi, N.; Chapanduka, Z. C. Hematological Findings in Adult Patients
- 493 with SARS CoV- 2 Infection at Tygerberg Hospital Cape Town South Africa. *Heal.*
- 494 *Sci. Reports* **2022**, 5 (3), 1–9. https://doi.org/10.1002/hsr2.550.
- 495 (15) Guan, W.; Ni, Z.; Hu, Y.; Liang, W.; Ou, C.; He, J.; Liu, L.; Shan, H.; Lei, C.; Hui, D. S.
- 496 C.; Du, B.; Li, L.; Zeng, G.; Yuen, K.-Y.; Chen, R.; Tang, C.; Wang, T.; Chen, P.;
- 497 Xiang, J.; Li, S.; Wang, J.; Liang, Z.; Peng, Y.; Wei, L.; Liu, Y.; Hu, Y.; Peng, P.;
- 498 Wang, J.; Liu, J.; Chen, Z.; Li, G.; Zheng, Z.; Qiu, S.; Luo, J.; Ye, C.; Zhu, S.; Zhong,
- 499 N. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med.
- 500 **2020**, 382 (18), 1708–1720. https://doi.org/10.1056/nejmoa2002032.
- 501 (16) Chong, V. C. L.; Lim, K. G. E.; Fan, B. E.; Chan, S. S. W.; Ong, K. H.; Kuperan, P.
- 502 Reactive Lymphocytes in Patients with COVID- 19. *Br. J. Haematol.* **2020**, *189* (5),
- 503 844–844. https://doi.org/10.1111/bjh.16690.
- 504 (17) Fan, B. E.; Chong, V. C. L.; Chan, S. S. W.; Lim, G. H.; Lim, K. G. E.; Tan, G. B.;
- 505 Mucheli, S. S.; Kuperan, P.; Ong, K. H. Hematologic Parameters in Patients with

506 COVID-19 Infection. *Am. J. Hematol.* **2020**, 95 (6), E131–E134.

- 507 https://doi.org/10.1002/ajh.25774.
- 508 (18) Henry, B. M.; De Oliveira, M. H. S.; Benoit, S.; Plebani, M.; Lippi, G. Hematologic,
- 509 Biochemical and Immune Biomarker Abnormalities Associated with Severe Illness
- and Mortality in Coronavirus Disease 2019 (COVID-19): A Meta-Analysis. *Clinical*
- 511 *Chemistry and Laboratory Medicine*. De Gruyter June 2020, pp 1021–1028.
- 512 https://doi.org/10.1515/cclm-2020-0369.
- 513 (19) Jiang, S.; Huang, Q.; Xie, W.; Lv, C.; Quan, X. The Association between Severe

- 514 COVID-19 and Low Platelet Count: Evidence from 31 Observational Studies Involving
- 515 7613 Participants. *Br. J. Haematol.* **2020**, *190* (1), e29–e33.
- 516 https://doi.org/10.1111/bjh.16817.
- 517 (20) Chen, T.; Guestrin, C. XGBoost: A Scalable Tree Boosting System. Proc. ACM
- 518 SIGKDD Int. Conf. Knowl. Discov. Data Min. **2016**, 13-17-Augu, 785–794.
- 519 https://doi.org/10.1145/2939672.2939785.
- 520 (21) Wool, G. D.; Miller, J. L. The Impact of COVID-19 Disease on Platelets and
- 521 Coagulation. *Pathobiology* **2021**, 88 (1), 15–27. https://doi.org/10.1159/000512007.
- 522 Figure 1: Haematological features used in different datasets. The green colour indicated the
- 523 presence of a particular feature in a dataset and the red colour indicated its absence.



525

526

527 Figure 2: Description of data sources used for training and prediction of different ML-models

528 based on haematological features for COVID-19 characterization



530

531

Figure 3: Pearson correlation coefficients between SARS-COV-2 results and individual features for a) dataset 1 b) dataset 2a and c) dataset 3a. Parameters with higher correlation (> \sim ±0.2) are shown in blue, remaining values in black, with an exception for dataset 3a (correlation cut off ±0.1).







536

537

Figure 4: Receiver Operating Characteristics Curves (ROC) across different ML models for a)
Dataset 1 b) Dataset 1a, c) Dataset 1b, d) Dataset 1c, e) Dataset 2a, f) Dataset 2b, g) Dataset
3a and h) Dataset 3b

medRxiv preprint doi: https://doi.org/10.1101/2023.03.07.23286949; this version posted March 8, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.





544 Figure 5: Comparative performances of different datasets trained on XGBoost model. The

545 datasets with published AUC scores are shown in brown bars for the following datasets (1b

546 and $1c)^9$ and $2a^{11}$.



547

548

Figure 6: Distributions of four hematological parameters across four different datasets (two training datasets – Dataset 1c and Dataset 2b and two test datasets –*early* and *advance*). The hematological parameters are – a) platelet, b) leukocyte c) eosinophil and d) monocyte. These distributions indicate the proximity of the individual test datasets to the training datasets



Figure 7: COVID-19 prediction server based on hematological parameters, a) home page b) 554

4-parameter prediction model and c) 14-parameter prediction model 555

